T. Rowe Price Associates’s Castle Biosciences CSTL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $540K | Buy |
26,407
+2,702
| +11% | +$55.3K | ﹤0.01% | 2265 |
|
|
2025
Q1 | $475K | Buy |
23,705
+1,008
| +4% | +$20.2K | ﹤0.01% | 2264 |
|
|
2024
Q4 | $605K | Buy |
22,697
+1,837
| +9% | +$49K | ﹤0.01% | 2195 |
|
|
2024
Q3 | $595K | Buy |
20,860
+212
| +1% | +$6.05K | ﹤0.01% | 2183 |
|
|
2024
Q2 | $450K | Buy |
20,648
+2,614
| +14% | +$57K | ﹤0.01% | 2226 |
|
|
2024
Q1 | $400K | Buy |
18,034
+1,131
| +7% | +$25.1K | ﹤0.01% | 2294 |
|
|
2023
Q4 | $365K | Buy |
16,903
+428
| +3% | +$9.24K | ﹤0.01% | 2310 |
|
|
2023
Q3 | $279K | Buy |
16,475
+1,009
| +7% | +$17.1K | ﹤0.01% | 2356 |
|
|
2023
Q2 | $213K | Buy |
15,466
+182
| +1% | +$2.51K | ﹤0.01% | 2502 |
|
|
2023
Q1 | $348K | Buy |
15,284
+303
| +2% | +$6.9K | ﹤0.01% | 2271 |
|
|
2022
Q4 | $353K | Sell |
14,981
-1,615
| -10% | -$38.1K | ﹤0.01% | 2310 |
|
|
2022
Q3 | $433K | Buy |
16,596
+2,957
| +22% | +$77.2K | ﹤0.01% | 2191 |
|
|
2022
Q2 | $299K | Sell |
13,639
-28
| -0.2% | -$614 | ﹤0.01% | 2434 |
|
|
2022
Q1 | $613K | Buy |
13,667
+3,723
| +37% | +$167K | ﹤0.01% | 2241 |
|
|
2021
Q4 | $426K | Buy |
9,944
+3,209
| +48% | +$137K | ﹤0.01% | 2460 |
|
|
2021
Q3 | $448K | Buy |
6,735
+1,363
| +25% | +$90.7K | ﹤0.01% | 2421 |
|
|
2021
Q2 | $394K | Buy |
5,372
+792
| +17% | +$58.1K | ﹤0.01% | 2477 |
|
|
2021
Q1 | $314K | Buy |
4,580
+679
| +17% | +$46.6K | ﹤0.01% | 2547 |
|
|
2020
Q4 | $262K | Buy |
+3,901
| New | +$262K | ﹤0.01% | 2468 |
|